Characteristics | Placebo, n = 12 | POM 1 mg QD, n = 10 |
---|---|---|
Age, yrs, mean (SD) | 44.8 (13.8) | 49.8 (9.9) |
Female | 10 (83.3) | 9 (90.0) |
Race | ||
White | 10 (83.3) | 7 (70.0) |
Asian | 0 (0.0) | 2 (20.0) |
Hawaiian Islander | 1 (8.3) | 0 (0.0) |
Black | 0 (0.0) | 1 (10.0) |
Missing | 1 (8.3) | 0 (0.0) |
Weight, kg, mean (SD) | 80.5 (14.2) | 70.8 (25.2) |
BMI, kg/m2, mean (SD) | 30.64 (5.4) | 26.67 (9.3) |
Disease type | ||
Diffuse | 9 (75.0) | 8 (80.0) |
Limited | 3 (25.0) | 2 (20.0) |
Calcium channel blockers | 2 (16.7) | 4 (40.0) |
Systemic corticosteroids | 5 (41.7) | 7 (70.0) |
Drugs for acid-related disorders* | 4 (33.3) | 7 (70.0) |
Note: The n reflects the no. randomized patients who received at least 1 dose of investigational study drug.
↵* Esomeprazole, omeprazole, pantoprazole, or sucralfate. POM: pomalidomide; QD: once daily; BMI: body mass index.